XOMA News and Press, XOMA Corporation From 12/21/20

EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the closing of its previously announced underwritten registered public offering of 984,000 shares, which includes the underwriters opti...

XOMA ([[XOMA]] -1.8%) announced the pricing of its underwritten registered public offering of 880k shares of 8.625% Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25/share at an initial public offering price of $25/share, expected gross proceeds of $22M.Underwr...

EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the pricing of its underwritten registered public offering of 880,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock, w...

EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of shares of its Series A Cumulative Perpetual Preferred Stock, with liquid...

XOMA (XOMA) earned a $2M milestone payment from Takeda Pharmaceutical as the first patient has been dosed in its Phase 2 study to evaluate safety, tolerability, and efficacy of mezagitamab (TAK-079) in participants with generalized myasthenia gravis.XOMA and Takeda entered into a collaboratio...

EMERYVILLE, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $2 million milestone payment from Takeda Pharmaceutical Company Limited as the first patient has been dosed in its Phas...

XOMA (XOMA) earned a $1M milestone payment from Agenus (AGEN) related to Merck's advancement of MK-4830 into a Phase 2 study in patients with advanced non-small cell lung cancer previously treated with anti-programmed cell death receptor ligand 1 therapy.MK-4830 is part of the company's first...

EMERYVILLE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $1 million milestone payment from Agenus Inc. (NASDAQ: AGEN) related to Merck’s advancement of MK-4830 into a Ph...

XOMA (XOMA): Q3 GAAP EPS of -$0.10 beats by $0.03.Revenue of $0.6M (-93.0% Y/Y) misses by $2.29M.Cash balance of $45.7M.Press Release For further details see: XOMA EPS beats by $0.03, misses on revenue

Company recently earned a $ 25 million milestone payment as NIS793 advanced to Phase 2 development in advanced pancreatic cancer An u ndisclosed partner entered Phase 2 development, triggering a $0.5 million milestone Rezolute’s financing res...